|
|
-
BioMarin Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5/20/2013
|
-
BioMarin Pharma To Release Data From Ongoing Phase 1/2 Trial For BMN-673
5/16/2013
|
|
|
-
BioMarin Q1 Loss Per Share $0.31 Vs Loss $0.21 Last Year
4/25/2013
|
|
|
-
BioMarin Submits Vimizim MAA To EMA For Treatment Of MPS IVA
4/24/2013
|
|
|
-
BioMarin Pharma Submits Clinical Trial Application For BMN-190 To Treat Patients With Batten Disease
4/1/2013
|
-
BioMarin Pharma Submits BLA To FDA For Vimizim For Mucopolysaccharidosis Type IVA
4/1/2013
|